+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ibandronate"

From
Osteoporosis Drugs Market Report 2025 - Product Thumbnail Image

Osteoporosis Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Osteoporosis Treatment Market Report 2025 - Product Thumbnail Image

Osteoporosis Treatment Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
Postmenopausal Osteoporosis - Pipeline Insight, 2025 - Product Thumbnail Image

Postmenopausal Osteoporosis - Pipeline Insight, 2025

  • Drug Pipelines
  • March 2025
  • 60 Pages
  • Global
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Ibandronate is a medication used to treat osteoporosis and other bone diseases. It belongs to a class of drugs known as bisphosphonates, which are used to reduce the risk of fractures in people with weakened bones. Ibandronate works by slowing down the breakdown of bone and increasing bone density. It is also used to treat Paget's disease of bone, a condition in which the bones become weak and deformed. Ibandronate is available in both oral and intravenous forms. The oral form is taken once a month, while the intravenous form is given every three months. Common side effects of ibandronate include nausea, vomiting, constipation, and abdominal pain. Ibandronate is a key player in the Endocrine and Metabolic Disorders Drugs market. It is used to treat a variety of bone diseases, including osteoporosis, and is an important part of the treatment regimen for these conditions. Some companies in the Ibandronate market include Amgen, Novartis, and Teva Pharmaceuticals. Show Less Read more